Liminatus Pharma Inc. (NASDAQ:LIMN) Sees Large Decrease in Short Interest

Liminatus Pharma Inc. (NASDAQ:LIMN) saw a significant drop in short interest in December. As of December 15th, there was short interest totaling 120,590 shares, a drop of 46.1% from the November 30th total of 223,895 shares. Based on an average daily volume of 137,849 shares, the short-interest ratio is currently 0.9 days. Currently, 0.4% of the company’s stock are sold short. Currently, 0.4% of the company’s stock are sold short. Based on an average daily volume of 137,849 shares, the short-interest ratio is currently 0.9 days.

Liminatus Pharma Stock Down 8.6%

Liminatus Pharma stock opened at $0.65 on Friday. The company’s 50 day moving average is $1.02. Liminatus Pharma has a twelve month low of $0.61 and a twelve month high of $33.66. The company has a market cap of $17.52 million and a P/E ratio of -5.39.

Liminatus Pharma (NASDAQ:LIMN) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.07) EPS for the quarter.

Analyst Ratings Changes

Several equities analysts have commented on LIMN shares. Wall Street Zen cut shares of Liminatus Pharma from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Liminatus Pharma in a research report on Monday. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

About Liminatus Pharma

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.